Literature DB >> 8032645

Differential effects of suramin on P2-purinoceptors mediating contraction of the guinea-pig vas deferens and urinary bladder.

S J Bailey1, S M Hourani.   

Abstract

1. The effect of the P2-purinoceptor antagonist, suramin, was investigated on contractions of the guinea-pig vas deferens and urinary bladder induced by adenosine 5'-triphosphate (ATP) and by the other naturally occurring nucleoside triphosphates. 2. ATP, guanosine 5'-triphosphate (GTP), cytidine 5'-triphosphate (CTP), inosine 5'-triphosphate (ITP) and uridine 5'-triphosphate (UTP) (0.1-500 microM) each contracted both the guinea-pig bladder and the guinea-pig vas deferens. In the vas deferens the order of potency of the nucleotides was ATP >> CTP > GTP > or = UTP = ITP, and in the bladder it was ATP >> CTP = GTP > UTP = ITP, although maximal responses to these agonists were not achieved in either tissue. 3. Suramin (30 microM-1 mM) dose-dependently inhibited ATP-induced contractions of the bladder in an apparently non-competitive manner, causing a reduction in the slope of the concentration-response curve to ATP. In contrast, suramin (5 microM-1 mM) had little inhibitory effect on ATP-induced contractions of the vas deferens, and indeed at concentrations of 100 microM and above markedly potentiated high concentrations of ATP (100-500 microM). The contractions induced by CTP, GTP, UTP and ITP (1-500 microM) were, however, abolished by suramin (1 mM) in each tissue. 4. Desensitization of the P2X purinoceptors in the guinea-pig vas deferens with adenosine 5'-alpha,beta-methylenetriphosphonate (AMPCPP) (300 microM) abolished contractions induced by ATP (1 microM-1 mM) in the absence of suramin. However, the contractions induced in the presence of suramin were unaffected by prior desensitization, indicating that they were not mediated by P2X-purinoceptors.5. ATP (100 MicroM) was dephosphorylated by both isolated tissue preparations under the conditions of these experiments, breakdown products being detectable after 2 min, with the major breakdown product in the bladder being inosine whereas that in the vas deferens was adenosine. Approximately 35% of the ATP remained intact after incubation for 30 min with the bladder, and approximately 45% remained after incubation for 30 min with the vas deferens. In each tissue this degradation was inhibited by suramin (1 mM), so that after incubation of ATP (100 MicroM) in the presence of suramin for 30 min,approximately 50% remained in the case of the bladder and approximately 65% remained in the vas deferens. However, inhibition of the production of the inhibitory agonist, adenosine by suramin did not appear to be responsible for the potentiation observed in the vas deferens, as the PI-purinoceptor antagonist 8-sulphophenyltheophylline (100 MicroM) did not reduce this potentiation.6. Chelation of divalent cations did not appear to account for the enhancement by suramin of ATP-induced contractions of the vas deferens, as the enhancement was still observed when Mg2+ was omitted from the buffer or when its concentration (normally 1.2 mM) was increased ten fold to 12 mM,or when the concentration of Ca2+ (normally 2.5 mM) was reduced to 0.83 mM. Even in the absence of Mg2+ and with the Ca2+ concentration reduced to 0.83 mM, no inhibition by suramin (1 mM) of ATP-induced contractions was observed.7. The most likely explanation for the potentiation by suramin of the ATP-induced contractions of the vas deferens is the co-existence of inhibitory P2Y-purinoceptors. However, no consistent relaxations to ATP (1-100 MicroM) or to the more potent P2Y-purinoceptor agonist 2-methylthioadenosine 5'-triphosphate(2-MeSATP) (0.01-100 MicroM) could be detected in the vas deferens precontracted with KCl (35 mM), even after desensitization of P2x-purinoceptors with AMPCPP (300 MicroM). Similarly, ATP (1-100 MicroM) or 2-MeSATP (0.01-1100 MicroM) added before KCI (35 mM), carbachol (10 JM) or noradrenaline (10 MicroM) did not reduce subsequent contractions to these agents.8. The differential effect of suramin on the contractions induced by ATP in the bladder and the vas deferens was unexpected, and shows that the receptor populations by which ATP acts in these tissues may not be identical. The failure of suramin to inhibit responses to ATP in the vas deferens suggests that this tissue, in addition to possessing P2x-purinoceptors may also possess a suramin-insensitive contractile ATP receptor revealed in the presence of suramin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032645      PMCID: PMC1910307          DOI: 10.1111/j.1476-5381.1994.tb13055.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  Expression cloning of an ATP receptor from mouse neuroblastoma cells.

Authors:  K D Lustig; A K Shiau; A J Brake; D Julius
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

2.  The structure-activity relationships of ectonucleotidases and of excitatory P2-purinoceptors: evidence that dephosphorylation of ATP analogues reduces pharmacological potency.

Authors:  L A Welford; N J Cusack; S M Hourani
Journal:  Eur J Pharmacol       Date:  1987-09-02       Impact factor: 4.432

Review 3.  Is there a basis for distinguishing two types of P2-purinoceptor?

Authors:  G Burnstock; C Kennedy
Journal:  Gen Pharmacol       Date:  1985

4.  ATP analogues and the guinea-pig taenia coli: a comparison of the structure-activity relationships of ectonucleotidases with those of the P2-purinoceptor.

Authors:  L A Welford; N J Cusack; S M Hourani
Journal:  Eur J Pharmacol       Date:  1986-10-07       Impact factor: 4.432

5.  Some pharmacological and biochemical interactions of the enantiomers of adenylyl 5'-(beta, gamma-methylene)-diphosphonate with the guinea-pig urinary bladder.

Authors:  N J Cusack; S M Hourani
Journal:  Br J Pharmacol       Date:  1984-05       Impact factor: 8.739

6.  Interaction of [3H]arylazido aminopropionyl ATP ([3H]ANAPP3) with P2-purinergic receptors in the smooth muscle of the isolated guinea-pig vas deferens.

Authors:  J S Fedan; G K Hogaboom; J P O'Donnell; S J Jeng; R J Guillory
Journal:  Eur J Pharmacol       Date:  1985-01-15       Impact factor: 4.432

7.  Studies on the stereoselectivity of the P2-purinoceptor on the guinea-pig vas deferens.

Authors:  G Burnstock; N J Cusack; L A Meldrum
Journal:  Br J Pharmacol       Date:  1985-02       Impact factor: 8.739

8.  Further comparison of contractions of the smooth muscle of the guinea-pig isolated vas deferens induced by ATP and related analogs.

Authors:  J S Fedan; G K Hogaboom; J P O'Donnell
Journal:  Eur J Pharmacol       Date:  1986-10-07       Impact factor: 4.432

9.  Response of the guinea-pig urinary bladder to purine and pyrimidine nucleotides.

Authors:  P Lukacsko; R D Krell
Journal:  Eur J Pharmacol       Date:  1982-06-04       Impact factor: 4.432

10.  Studies on the stereoselectivity of the P2-purinoceptor.

Authors:  G Burnstock; N J Cusack; J M Hills; I MacKenzie; P Meghji
Journal:  Br J Pharmacol       Date:  1983-08       Impact factor: 8.739

View more
  15 in total

1.  P2X receptor expression in mouse urinary bladder and the requirement of P2X(1) receptors for functional P2X receptor responses in the mouse urinary bladder smooth muscle.

Authors:  C Vial; R J Evans
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Co-existence of P2Y-and PPADS-insensitive P2U-purinoceptors in endothelial cells from adrenal medulla.

Authors:  J Mateo; M T Miras-Portugal; E Castro
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

3.  Enhancement of sympathetic purinergic neurotransmission in the guinea-pig isolated vas deferens by the novel ecto-ATPase inhibitor ARL 67156.

Authors:  T D Westfall; C Kennedy; P Sneddon
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 4.  New insights on P2X purinoceptors.

Authors:  P P Humphrey; G Buell; I Kennedy; B S Khakh; A D Michel; A Surprenant; D J Trezise
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

5.  Individual sympathetic varicosities possess different sensitivities to alpha 2 and P2 receptor agonists and antagonists in mouse vas deferens.

Authors:  S C O'Connor; K L Brain; M R Bennett
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

6.  Release of ATP in rat vas deferens: origin and role of calcium.

Authors:  A K Kurz; R Bültmann; B Driessen; I von Kügelgen; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

7.  Functional consequences of inhibition of nucleotide breakdown in rat vas deferens: a study with Evans blue.

Authors:  R Bültmann; B Driessen; J Gonçalves; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

8.  Action of suramin upon ecto-apyrase activity and synaptic depression of Torpedo electric organ.

Authors:  E Martí; C Cantí; I Gómez de Aranda; F Miralles; C Solsona
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

9.  Corelease of noradrenaline and ATP by brief pulse trains in guinea-pig vas deferens.

Authors:  I von Kügelgen; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

10.  Evidence for a P2-purinoceptor mediating vasoconstriction by UTP, ATP and related nucleotides in the isolated pulmonary vascular bed of the rat.

Authors:  A Rubino; G Burnstock
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.